COMP <GO>
QCLS vs BMRA // REVENUE GROWTH (YOY)
Q/C Technologies Inc. (NASDAQ) VS. Biomerica Inc. (NASDAQ) • 15-METRIC TALLY: QCLS 0
— BMRA 2
■ METRIC PARITY
LAST: $0.44 (-3.44%) • MKT CAP: $3.6M
revenue-growth
—
LAST: $1.74 (-0.57%) • MKT CAP: $8.0M
revenue-growth
-16.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QCLS VS. BMRA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QCLS | BMRA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 8.10% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | -16.20% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.9 | 37.0 | -9.11 | BMRA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.6M | $8.0M | -$4.4M | BMRA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QCLS REV | BMRA REV | QCLS GROSS % | BMRA GROSS % | QCLS FCF | BMRA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $4.5M | — | 8.1% | -$9.1M | -$3.4M |
| FY 2024 | $0 | $5.3M | — | 9.4% | -$9.0M | -$3.8M |
| FY 2023 | $0 | $5.4M | — | — | -$13.0M | -$5.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QCLS // BETA —
BMRA // BETA —